Question

In: Finance

Sunland Industries is expanding its product line and its production capacity. The costs and expected cash...

Sunland Industries is expanding its product line and its production capacity. The costs and expected cash flows of the two independent projects are given in the following table. The firm uses a discount rate of 16.08 percent for such projects. Year Product Line Expansion Production Capacity Expansion 0 -$2,053,800 -$6,584,800 1 663,900 2,742,200 2 839,000 2,742,200 3 839,000 2,742,200 4 839,000 2,612,300 5 839,000 2,612,300 a. What are the NPVs of the two projects? (Enter negative amounts using negative sign, e.g. -45.25. Do not round discount factors. Round other intermediate calculations and final answer to 0 decimal places, e.g. 1,525.) NPV of product line expansion is $ NPV of production capacity expansion is $ b. Should both projects be accepted? or either? or neither? Explain your reasoning. Sunland should accept .

Solutions

Expert Solution

Product Line

Net present value is solved using a financial calculator. The steps to solve on the financial calculator:

  • Press the CF button.
  • CF0= -$2,053,800. It is entered with a negative sign since it is a cash outflow.
  • Cash flow for all the years should be entered.
  • Press Enter and down arrow after inputting each cash flow.
  • After entering the last cash flow, press the NPV button and enter the discount rate of 16.08%.
  • Press the down arrow and CPT buttons to get the net present value.

Net Present value of cash flows at 16.08% discount rate is $537,369.

Production Capacity

Net present value is solved using a financial calculator. The steps to solve on the financial calculator:

  • Press the CF button.
  • CF0= -$6,584,800. It is entered with a negative sign since it is a cash outflow.
  • Cash flow for all the years should be entered.
  • Press Enter and down arrow after inputting each cash flow.
  • After entering the last cash flow, press the NPV button and enter the discount rate of 16.08%.
  • Press the down arrow and CPT buttons to get the net present value.

Net Present value of cash flows at 16.08% discount rate is $2,244,058.

The company should accept both projects since they have the positive net present value.

Projects with a positive net present value are accepted in case of independent projects.

In case of any query, kindly comment on the solution.


Related Solutions

Cullumber Industries is expanding its product line and its production capacity. The costs and expected cash...
Cullumber Industries is expanding its product line and its production capacity. The costs and expected cash flows of the two independent projects are given in the following table. The firm uses a discount rate of 10.54 percent for such projects. Year Product Line Expansion Production Capacity Expansion 0 -$3,146,400 -$9,369,900 1 741,600 2,699,400 2 895,900 2,699,400 3 895,900 2,699,400 4 895,900 3,978,600 5 895,900 3,978,600 a. What are the NPVs of the two projects? (Enter negative amounts using negative sign,...
Crane Industries is expanding its product line and its production capacity. The costs and expected cash...
Crane Industries is expanding its product line and its production capacity. The costs and expected cash flows of the two independent projects are given in the following table. The firm uses a discount rate of 14.08 percent for such projects. Year Product Line Expansion Production Capacity Expansion 0 -$2,233,600 -$9,704,800 1 478,900 2,611,700 2 980,500 2,611,700 3 980,500 2,611,700 4 980,500 3,361,400 5 980,500 3,361,400 a. What are the NPVs of the two projects? (Enter negative amounts using negative sign,...
Cullumber Industries is expanding its product line and its production capacity. The costs and expected cash...
Cullumber Industries is expanding its product line and its production capacity. The costs and expected cash flows of the two independent projects are given in the following table. The firm uses a discount rate of 14.98 percent for such projects. Year Product Line Expansion Production Capacity Expansion 0 -$2,426,500 -$6,756,300 1 501,800 2,381,500 2 853,000 2,381,500 3 853,000 2,381,500 4 853,000 3,975,200 5 853,000 3,975,200 a. What are the NPVs of the two projects? b. Should both projects be accepted?...
Crane Industries is expanding its product line and its production capacity. The costs and expected cash...
Crane Industries is expanding its product line and its production capacity. The costs and expected cash flows of the two independent projects are given in the following table. The firm uses a discount rate of 14.08 percent for such projects. Year Product Line Expansion Product capacity expansion 0 -$2,233,600 -$9,704,800 1 478,900 2,611,700 2 980,500 2,611,700 3 980,500 2,611,700 4 980,500 3,361,400 5 980,500 3,361,400 a. What are the NPVs of the two projects? (Enter negative amounts using negative sign,...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of products. Current plans call for the expenditure of $100 million on four projects of equal size ($25 million each), but different returns. Project A is in blood clotting proteins and has an expected return of 18 percent. Project B relates to a hepatitis vaccine and carries a potential return of 14 percent. Project C, dealing with a cardiovascular compound, is expected to earn 11.8...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of products. Current plans call for the expenditure of $100 million on four projects of equal size ($25 million each), but different returns. Project A is in blood clotting proteins and has an expected return of 18 percent. Project B relates to a hepatitis vaccine and carries a potential return of 14 percent. Project C, dealing with a cardiovascular compound, is expected to earn 11.8...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of products. Current plans call for the expenditure of $100 million on four projects of equal size ($25 million each), but different returns. Project A is in blood clotting proteins and has an expected return of 18 percent. Project B relates to a hepatitis vaccine and carries a potential return of 14 percent. Project C, dealing with a cardiovascular compound, is expected to earn 11.8...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of products. Current plans call for the expenditure of $100 million on four projects of equal size ($25 million each), but different returns. Project A is in blood clotting proteins and has an expected return of 18 percent. Project B relates to a hepatitis vaccine and carries a potential return of 14 percent. Project C, dealing with a cardiovascular compound, is expected to earn 11.8...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of products. Current plans call for the expenditure of $100 million on four projects of equal size ($25 million each), but different returns. Project A is in blood clotting proteins and has an expected return of 18 percent. Project B relates to a hepatitis vaccine and carries a potential return of 14 percent. Project C, dealing with a cardiovascular compound, is expected to earn 11.8...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of...
Medical Research Corporation is expanding its research and production capacity to introduce a new line of products. Current plans call for the expenditure of $100 million on four projects of equal size ($25 million each), but different returns. Project A is in blood clotting proteins and has an expected return of 18 percent. Project B relates to a hepatitis vaccine and carries a potential return of 14 percent. Project C, dealing with a cardiovascular compound, is expected to earn 11.8...
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT